Trials / Recruiting
RecruitingNCT06803589
Growth Hormone for the Treatment of Gastroparesis
Low-dose Growth Hormone for the Treatment of Gastroparesis
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Growth Hormone | Subjects will receive somapacitan-beco (Sogroya®) administered as a subcutaneous injection once weekly for 12 weeks. All participants will receive a fixed dose of 1.5 mg weekly, regardless of sex. |
Timeline
- Start date
- 2024-10-22
- Primary completion
- 2027-10-01
- Completion
- 2027-12-01
- First posted
- 2025-01-31
- Last updated
- 2026-04-16
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06803589. Inclusion in this directory is not an endorsement.